Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19

Abstract

Neurological long-term sequelae are increasingly considered an important challenge in the recent COVID-19 pandemic. However, most evidence for neurological symptoms after SARS-CoV-2 infection and central nervous system invasion of the virus stems from individuals severely affected in the acute phase of the disease. Here, we report long-lasting cognitive impairment along with persistent cerebrospinal fluid anti-SARS-CoV-2 antibodies in a female patient with unremarkable standard examination 6 months after mild COVID-19, supporting the implementation of neuropsychological testing and specific cerebrospinal fluid investigation also in patients with a relatively mild acute disease phase.

Original languageEnglish
JournalNeurological research and practice
Volume3
Issue number1
Pages (from-to)34
ISSN2524-3489
DOIs
Publication statusPublished - 21.06.2021

Research Areas and Centers

  • Research Area: Medical Genetics
  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

DFG Research Classification Scheme

  • 206-07 Clinical Neurology Neurosurgery and Neuroradiology
  • 205-13 Pneumology, Thoracal Surgery
  • 204-05 Immunology
  • 204-04 Virology

Coronavirus related work

  • Research on SARS-CoV-2 / COVID-19

Fingerprint

Dive into the research topics of 'Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19'. Together they form a unique fingerprint.

Cite this